BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Practice Updates in Advanced RCC

Expert Perspective Tumor Board

Oncology specialists analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic renal cell carcinoma.

Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

Videos

Led by Dr Katy Beckermann, medical experts navigate three clinical cases, the patient journey, and updates from key clinical trial results.

Dr Katy Beckermann introduces the panel of experts and addresses the first clinical case in this series, highlighting intermediate-risk, metastatic clear cell renal cell carcinoma.

Clinical Case: Intermediate-Risk, Metastatic Clear Cell Renal Cell Carcinoma

Renal cell carcinoma experts examines risk stratification strategies to guide their treatment approaches for a 59-year-old woman with RCC.

Risk Stratifying Patients with RCC: Making Informed Decisions

Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.

First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

A panel of renal cell carcinoma experts deliberates on the treatment approach for a 59-year-old woman diagnosed with a left renal mass.

Treatment Recommendations for a 59-Year-Old Woman with RCC

Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.

Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy

Renal cell carcinoma specialists analyze the case of a 59-year-old woman with RCC, focusing on the partial response observed on CT imaging four months after initiating combination therapy with nivolumab and ipilimumab.

Patient Case: Workup and Imaging in RCC

Medical experts examine the case of a 61-year-old male patient with a history of low-volume, indolent metastatic clear cell renal cell carcinoma, who has undergone left nephrectomy and adrenalectomy.

Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC

Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.

First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

Medical experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in renal cell carcinoma patients treated with immune checkpoint inhibitor and tyrosine kinase inhibitor combinations.

Optimizing ICI and TKI Combinations + Dose Reductions

Renal cell carcinoma specialists continue analyzing the case of a 61-year-old patient with indolent metastatic clear cell RCC, evaluating available therapeutic options, discussing disease progression, and addressing recent changes in treatment guidelines.

Indolent Metastatic ccRCC Disease Progression and Guideline Updates

Oncology experts examine their patient population demographics and discuss the percentage of clear cell renal cell carcinoma patients who progress to receive third-line and subsequent lines of therapy.

Third-Line Therapy for Patients with ccRCC

Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical data to inform their treatment approach for renal cell carcinoma.

Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain

Renal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.

First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features

Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

EP: 1.Clinical Case: Intermediate-Risk, Metastatic Clear Cell Renal Cell Carcinoma

EP: 2.Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

EP: 3.Risk Stratifying Patients with RCC: Making Informed Decisions

EP: 4.First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

EP: 5.Treatment Recommendations for a 59-Year-Old Woman with RCC

EP: 6.Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy

EP: 7.Patient Case: Workup and Imaging in RCC

EP: 8.Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC

EP: 9.First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

EP: 10.Optimizing ICI and TKI Combinations + Dose Reductions

EP: 11.Indolent Metastatic ccRCC Disease Progression and Guideline Updates

EP: 12.Third-Line Therapy for Patients with ccRCC

EP: 13.Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain

EP: 14.First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features

Newsletter